N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,124 Acute Renal Failure Trial Network (ATN) Study
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
N/A N=1,001 Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU
Acute Kidney Injury
Primary: The Efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an Aid in the Diagnosis of Acute Kidney Injury (AKI) in an All-comers ICU Setting…
N/A N=81 Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.
End Stage Renal Disease
Primary: Number of Participants With Clinically Significant Cardiac Arrhythmias Using Continuous Cardiac Monitoring Over a 6-month Period With an Implanted Medtronic Reveal ICM…
Phase 3 N=294 RenalGuard System and Contrast Media
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
N/A N=5,060 Drug-Targeted Alerts for Acute Kidney Injury
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
N/A N=10,252 IMPROVE AKI Cluster-Randomized Trial
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
Phase 1 N=32 PF-04634817 Renal Impairment Study
Renal Insufficiency
Primary: Area Under the Curve From Time Zero to 48 Hours[AUC (0 - 48)] — 1294; 1399; 2024; 2860 Nanogram*hour/milliliter (ng*h/mL)
Phase 1 N=24 A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
Impaired Renal Function
Primary: Pharmacokinetic Parameters- Plasma AUC0-24 — 16877.94; 32787.41; 64895.29; 15506.68 ng*h/mL
Phase 2 N=234 Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Acute Kidney Injury
Primary: Number of Participants With Treatment-Emergent Adverse Events — 7; 7; 2; 1 Participants
N/A N=77 Protocol to Assess the Severity of Acute Kidney Injury
Acute Kidney Failure
Primary: Urine Volume — 89; 329; 96; 392 ml
N/A N=128 An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
Kidney Transplantation
Primary: Creatinine Clearance at 1 Month After Transplantation — 65.82 mL/min
N/A N=108 Trial Assessing Renal Damage During Ureteroscopy
Nephrolithiasis
Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml
Phase 1 N=29 A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Pneumonia
Primary: Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose — 17700; 22070; 28940; 10340 nanogram per milliliter (ng/mL)
Phase 1 N=31 Mild, Moderate and Severe Renal Impairment Study
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
Phase 3 N=128 Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients
Renal Transplantation
Primary: Time to First Occurrence of a Mycophenolic Acid (MPA) Plasma Concentration of ≥ 40 mg*h/L — 7.00; 43.00 Days
Phase 1 N=12 A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery
Acute Kidney Injury (AKI)
Primary: Frequency of Adverse Events (AEs) — 6; 1; 3; 1 Participants
Phase 2 N=12 Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function
Pharmacokinetics · Renal Impaired · Healthy Volunteer
Primary: Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5) — 0.5; 0.5; 0.5; 0.5 hour
Phase 1 N=30 Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
Renal Impairment · Healthy
Primary: Cmax — 545.4; 593.2; 475.9 ng/mL
N/A N=96 The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury
Acute Kidney Failure
Primary: Progression to Stage 3 AKI — 23 Participants
Phase 4 N=8 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
Phase 1 N=40 Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)
Healthy Volunteers · Renal Impairment
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Last Measurable Concentration (AUC0-last) of MK-6183 — 87.6; 114.8; 97.5; 228.0 ug*hr/mL
N/A N=1,674 Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Carcinoma, Renal Cell
Primary: Number of Participants With Treatment-Related Adverse Events — 1599 Participants
N/A N=3 Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
Chronic Kidney Diseases · Type 2 Diabetes
Primary: Glucose Time in Range — 495.2; 573.3 minutes per day
N/A N=396 Achieving Medication Safety During Acute Kidney Injury
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
N/A N=21 Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: Number of Participants Who Submitted at Least One Carevive Survey — 13 Participants
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
N/A N=4,003 Personalized Recommendations for Acute Kidney Injury (AKI) Care
Acute Kidney Injury
Primary: Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death — 369; 395…
Phase 4 N=32 Fondaparinux in Critically Ill Patients With Renal Failure
Venous Thromboembolism
Primary: To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels…